Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview

References

• Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 2010;48(Suppl 1):S2–7. doi:10.1016/S1386-6532(10)70002-0.
   PubMed Web of Science ®Google Scholar
• Cohen JI. Clinical practice: herpes zoster. N Engl J Med. 2013;369(3):255–63. doi:10.1056/NEJMcp1302674.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81(10):928–30. doi:10.1212/WNL.0b013e3182a3516e.
   PubMed Web of Science ®Google Scholar
• McKay SL, Guo A, Pergam SA, Dooling K. Herpes zoster risk in immunocompromised adults in the United States: a systematic review. Clin Infect Dis. 2020;71(7):e125–e134. doi:10.1093/cid/ciz1090.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Bresnitz E, Popmihajlov Z, Weinberg A, Liaw KL, Willis E, Curtis JR. Studies with herpes zoster vaccines in immune compromised patients. Expert Rev Vaccines. 2017;16(12):1217–30. doi:10.1080/14760584.2017.1395703.
   PubMed Web of Science ®Google Scholar
• Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato PW, Halsey NA, Gershon AA. Herpes zoster vaccine live: a 10 year review of post-marketing safety experience. Vaccine. 2017;35(52):7231–39. doi:10.1016/j.vaccine.2017.11.013.
   PubMed Web of Science ®Google Scholar
• Alexander KE, Tong PL, Macartney K, Beresford R, Sheppeard V, Gupta M. Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection. Vaccine. 2018;36(27):3890–93. doi:10.1016/j.vaccine.2018.05.078.
   PubMed Web of Science ®Google Scholar
• Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim S-J, Kim S-I, Zaltzman J, Ortiz F, Campistol Plana JM, Fernandez Rodriguez AM, Rebollo Rodrigo H, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase III, randomized clinical trial. Clin Infect Dis. 2020;70(2):181–90. doi:10.1093/cid/ciz177.
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC, Mossad SB, Andreadis C, Young JAH, Buadi FK, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124(19):2921–29. doi:10.1182/blood-2014-04-573048.
   PubMed Web of Science ®Google Scholar
• Bastidas A, De La Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123–33. doi:10.1001/jama.2019.9053.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Mullane KM, Cornely OA, Boeckh MJ, Brown JW, Pergam SA, Trociukas I, Žák P, Craig MD, Papanicolaou GA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10135):2116–27. doi:10.1016/s0140-6736(18)30631-7.
   PubMed Web of Science ®Google Scholar
• Mullane KM, Winston DJ, Wertheim MS, Betts RF, Poretz DM, Camacho LH, Pergam SA, Mullane MR, Stek JE, Sterling TM, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013;208(9):1375–85. doi:10.1093/infdis/jit344.
   PubMed Web of Science ®Google Scholar
• Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez Macías G, Chiou T-J, Quiel D, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988–1000. doi:10.1016/s1473-3099(19)30163-x.
   PubMed Web of Science ®Google Scholar
• Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio‐Viqueira B, Jung KH, Rodriguez Moreno JF, Grande E, Marrupe Gonzalez D, Lowndes S, Puente J, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019;125(8):1301–12. doi:10.1002/cncr.31909.
   PubMed Web of Science ®Google Scholar
• Berkowitz EM, Moyle G, Stellbrink HJ, Schurmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC, Brockmeyer N, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279–87. doi:10.1093/infdis/jiu606.
   PubMed Web of Science ®Google Scholar
• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. doi:10.1136/bmjopen-2014-004833.
   PubMed Web of Science ®Google Scholar
• Gilbert L, Wang X, Deiss R, Okulicz J, Maves R, Schofield C, Ferguson T, Whitman T, Kronmann K, Agan B, et al. Herpes zoster rates continue to decline in people living with human immunodeficiency virus but remain higher than rates reported in the general US population. Clin Infect Dis. 2019;69(1):155–58. doi:10.1093/cid/ciy1041.
   PubMed Web of Science ®Google Scholar
• Moanna A, Rimland D. Decreasing incidence of herpes zoster in the highly active antiretroviral therapy era. Clin Infect Dis. 2013;57(1):122–25. doi:10.1093/cid/cit165.
   PubMed Web of Science ®Google Scholar
• Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715–29. doi:10.1056/NEJMra033540.
   PubMed Web of Science ®Google Scholar
• Arness T, Pedersen R, Dierkhising R, Kremers W, Patel R. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. Transpl Infect Dis. 2008;10(4):260–68. doi:10.1111/j.1399-3062.2007.00289.x.
   PubMed Web of Science ®Google Scholar
• Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant. 2004;4(1):108–15. doi:10.1046/j.1600-6143.2003.00287.x.
   PubMed Web of Science ®Google Scholar
• Pergam SA, Forsberg CW, Boeckh MJ, Maynard C, Limaye AP, Wald A, Smith NL, Young BA. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis. 2011;13(1):15–23. doi:10.1111/j.1399-3062.2010.00547.x.
   PubMed Web of Science ®Google Scholar
• Koo S, Gagne LS, Lee P, Pratibhu PP, James LM, Givertz MM, Marty FM. Incidence and risk factors for herpes zoster following heart transplantation. Transpl Infect Dis. 2014;16(1):17–25. doi:10.1111/tid.12149.
   PubMed Web of Science ®Google Scholar
• Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R. Herpes zoster infection after autologous bone marrow transplantation. Blood. 1989;74(4):1424–27. doi:10.1182/blood.V74.4.1424.1424.
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Olivieri A, Mele A, Brunori M, Montanari M, Rupoli S, Scalari P, Leoni P. A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation. Clin Infect Dis. 2001;32(10):1414–22. doi:10.1086/320157.
   PubMed Web of Science ®Google Scholar
• Barton T, Collis T, Stadtmauer E, Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis. 2001;32(3):391–95. doi:10.1086/318491.
   PubMed Web of Science ®Google Scholar
• Kamber C, Zimmerli S, Suter-Riniker F, Mueller BU, Taleghani BM, Betticher D, Zander T, Pabst T. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients. Bone Marrow Transplant. 2015;50(4):573–78. doi:10.1038/bmt.2014.290.
   PubMed Web of Science ®Google Scholar
• Koc Y, Miller KB, Schenkein DP, Griffith J, Akhtar M, DesJardin J, Snydman DR. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant. 2000;6(1):44–49. doi:10.1016/s1083-8791(00)70051-6.
   PubMed Web of Science ®Google Scholar
• Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant. 2000;25(6):657–64. doi:10.1038/sj.bmt.1702190.
   PubMed Web of Science ®Google Scholar
• Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, Sato H, Watanabe T, Hosoya N, Izutsu K, et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2008;83(6):472–76. doi:10.1002/ajh.21152.
   PubMed Web of Science ®Google Scholar
• Habel LA, Ray GT, Silverberg MJ, Horberg MA, Yawn BP, Castillo AL, Quesenberry CP, Li Y, Sadier P, Tran TN, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(1):82–90. doi:10.1158/1055-9965.epi-12-0815.
   PubMed Web of Science ®Google Scholar
• Mao J, McPheeters JT, Finelli L. Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: a retrospective cohort study. Medicine (Baltimore). 2017;96(48):e8746. doi:10.1097/MD.0000000000008746.
   PubMed Web of Science ®Google Scholar
• Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, Campbell B, Su S-C, Chan ISF, Parrino J, et al. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2019;19(9):1001–12. doi:10.1016/s1473-3099(19)30310-x.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32. doi:10.1056/NEJMoa1603800.
   PubMed Web of Science ®Google Scholar
• Oostvogels L, Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van Den Steen P, Zahaf T, Dagnew AF, Chlibek R, Diez-Domingo J, et al. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vaccin Immunother. 2019;15(12):2865–72. doi:10.1080/21645515.2019.1627818.
   PubMed Web of Science ®Google Scholar
• Dagnew AF, Rausch D, Hervé C, Zahaf T, Levin MJ, Schuind A. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford). 2020. doi:10.1093/rheumatology/keaa1424.
   Web of Science ®Google Scholar
• Lopez-Fauqued M, Co M, Bastidas A, Beukelaers P, Dagnew AF, Fernandez Garcia JJ, Schuind A, Tavares da Silva F. Safety profile of the adjuvanted recombinant zoster vaccine (RZV) in immunocompromised populations: an overview of 6 trials. Open Forum Infect Dis. 2020;7(S1):S42–S43. doi:10.1093/ofid/ofaa439.082
   Google Scholar
• Stadtmauer EA, Sullivan KM, El Idrissi M, Salaun B, Alonso Alonso A, Andreadis C, Anttila VJ, Bloor AJC, Broady R, Cellini C, et al. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. Hum Vaccin Immunother. Under consideration.
   Google Scholar
• Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang S-J, McElhaney JE, Vesikari T, Andrews C, Choi WS, et al. Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J Infect Dis. 2018;217(11):1750–60. doi:10.1093/infdis/jiy095.
   PubMed Web of Science ®Google Scholar
• GSK Study Register. Clinical study reports for study IDs 115523, 116428, and 116886. [accessed 9 Sept 2020]. https://www.gsk-studyregister.com/en/
   Google Scholar
• Chlibek R, Smetana J, Pauksens K, Rombo L, Van Den Hoek JA, Richardus JH, Plassmann G, Schwarz TF, Ledent E, Heineman TC, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32(15):1745–53. doi:10.1016/j.vaccine.2014.01.019.
   PubMed Web of Science ®Google Scholar
• Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol. 2010;342:341–57. doi:10.1007/82_2010_31.
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Laupeze B, Di Pasquale A, Hergli N, Collignon C, Garcon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16(1):55–63. doi:10.1080/14760584.2016.1213632.
   PubMed Web of Science ®Google Scholar
• Berry N, Manoussaka M, Ham C, Ferguson D, Tudor H, Mattiuzzo G, Klaver B, Page M, Stebbings R, Das AT, et al. Role of occult and post-acute phase replication in protective immunity induced with a novel live attenuated SIV vaccine. PLoS Pathog. 2016;12(12):e1006083. doi:10.1371/journal.ppat.1006083.
   PubMed Web of Science ®Google Scholar
• Maggioli MF, Palmer MV, Thacker TC, Vordermeier HM, McGill JL, Whelan AO, Larsen MH, Jacobs Jr. WR, Waters WR. Increased TNF-alpha/IFN-gamma/IL-2 and Decreased TNF-alpha/IFN-gamma production by central memory T cells are associated with protective responses against bovine tuberculosis following BCG vaccination. Front Immunol. 2016;7:421. doi:10.3389/fimmu.2016.00421.
   PubMed Web of Science ®Google Scholar
• Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, Gmeiner M, Campo JJ, Esen M, Ruben AJ, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542(7642):445–49. doi:10.1038/nature21060.
   PubMed Web of Science ®Google Scholar
• Gross S, Erdmann M, Haendle I, Voland S, Berger T, Schultz E, Strasser E, Dankerl P, Janka R, Schliep S, et al. Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. JCI Insight. 2017;2(8):e91438. doi:10.1172/jci.insight.91438.
   PubMed Web of Science ®Google Scholar
• Lopez-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, Diez-Domingo J, Heineman TC, Lal H, McElhaney JE, et al. Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. Vaccine. 2019;37(18):2482–93. doi:10.1016/j.vaccine.2019.03.043.
   PubMed Web of Science ®Google Scholar